Akebia (AKBA) SVP Rucci sells shares to cover RSU tax withholding

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported multiple automatic stock sales tied to equity compensation. On February 2, 2026, she sold 16,846, 25,382, and 27,544 shares of Akebia common stock at $1.39 per share in separate transactions.

The filing states one sale was made under a Rule 10b5-1 trading plan adopted on September 8, 2025. The other sales were made automatically by Akebia to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on January 31, 2023, January 31, 2024, and January 31, 2025. After these transactions, Rucci directly beneficially owned 588,378 shares of common stock.

Insider Trade Summary

Net Seller: 69,772 shares ($96,983)

Net Sell 3 txns

Insider Rucci Carolyn M.

Role SVP, Chief Legal Officer

Sold 69,772 shs ($97K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,846	$1.39	$23K
Sale	Common Stock	25,382	$1.39	$35K
Sale	Common Stock	27,544	$1.39	$38K

Holdings After Transaction: Common Stock — 641,304 shares (Direct)

Footnotes (1)

This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

Form 4 Insider Transactions: What Each Field Means →

02/04/2026 - 04:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rucci Carolyn M.

(Last)

(First)

(Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST ST.

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/02/2026		S		16,846⁽¹⁾⁽²⁾	D	$1.39	641,304	D
Common Stock	02/02/2026		S		25,382⁽¹⁾⁽³⁾	D	$1.39	615,922	D
Common Stock	02/02/2026		S		27,544⁽¹⁾⁽⁴⁾	D	$1.39	588,378	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.

3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.

4. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

Remarks:

	/s/ John P. Butler, attorney-in-fact for Carolyn M. Rucci	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Akebia Therapeutics (AKBA) report for Carolyn M. Rucci?

Akebia reported that SVP and Chief Legal Officer Carolyn M. Rucci sold three blocks of common stock on February 2, 2026 at $1.39 per share. The transactions were routine equity-related sales, including trades under a Rule 10b5-1 plan and tax-withholding sales tied to restricted stock unit vesting.

How many Akebia (AKBA) shares did Carolyn M. Rucci sell on February 2, 2026?

Rucci sold 16,846, 25,382, and 27,544 Akebia common shares in three separate transactions on February 2, 2026. Each transaction was reported with a sale price of $1.39 per share, reflecting structured sales linked to her equity compensation arrangements and trading plan.

At what price were Carolyn M. Rucci’s Akebia (AKBA) shares sold?

All three reported sales of Akebia common stock by Carolyn M. Rucci were executed at $1.39 per share. The Form 4 lists each transaction separately but shows the same sale price, indicating the trades occurred at a consistent market level on the reported date.

How many Akebia (AKBA) shares does Carolyn M. Rucci own after these transactions?

After the reported February 2, 2026 transactions, Rucci beneficially owned 588,378 shares of Akebia common stock directly. This post-transaction balance reflects her remaining equity stake as disclosed in the Form 4’s ownership column following the series of sales.

Were Carolyn M. Rucci’s Akebia (AKBA) stock sales under a Rule 10b5-1 plan?

Yes, one of Rucci’s reported sales was made under a Rule 10b5-1 trading plan adopted on September 8, 2025. Rule 10b5-1 plans prearrange trading instructions, helping insiders sell shares on a scheduled basis independent of later material nonpublic information.

Why did Akebia (AKBA) automatically sell some of Carolyn M. Rucci’s shares?

Certain sales were made automatically by Akebia to cover Rucci’s tax withholding obligations on restricted stock unit vesting. These transactions related to the vesting and settlement of one-third of RSU grants awarded on January 31, 2023, January 31, 2024, and January 31, 2025.